Source: Annual Congress 2006 - Airway regulation, provocation and monitoring - III
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Bochenek, E. Nizankowska, K. Nagraba, A. Gielicz, A. Szczeklik (Kracow, Poland). Prostaglandin D₂ (PGD₂) and tryptase release into blood after adenosine and methacholine challenges in asthmatic patients. Eur Respir J 2006; 28: Suppl. 50, 3885

Member's Comments

No comment yet.

Related content which might interest you: Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum supernatant in smoking asthma Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Increased leukotriene and lower prostaglandin E2 concentrations in induced sputum of patients with eosinophilic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006 A leukotriene antagonist, montelukast, reduces in vitro LTD4 increases in peripheral blood eosinophil progenitor colonies in atopic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 531s Year: 2001 Dose-response of leukotriene CysLT1-receptor antagonist on nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: Suppl. 48, 585s Year: 2004 Thromboxane B2 and prostaglandin E2 concentrations in exhaled breath condensate in healthy volunteers and patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 509s Year: 2002 Bronchoconstriction induced by prostaglandin D2 (PGD2) in guinea pig lung is enhanced by selective COX-2 inhibition Source: Eur Respir J 2006; 28: Suppl. 50, 759s Year: 2006 Evidence of mast cell activation and leukotriene release after mannitol inhalation Source: Eur Respir J 2003; 22: 491-496 Year: 2003 Effect of airway provocation with histamine and adenosine 5’-monophosphate on sputum neutrophils and -related mediators Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004 Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004 Downregulation of prostaglandin E2 in bronchial fibroblasts of asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 95s Year: 2002 A novel protective role of prostaglandin D2 in antigen-induced bronchoconstriction Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Effect of combined leukotriene, histamine antagonism on the early response to inhaled allergen Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005 Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002 Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Source: Eur Respir J 2004; 23: 76-81 Year: 2004 Increased exhaled cysteinyl-leukotrienes, leukotriene B4 and 8-isoprostane in exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001 The adenosine A2A-Receptor is not involved in adenosine induced bronchoconstriction in asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003 Changes in sputum concentrations of leukotrienes and thromboxane after dry air hyperventilation in asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 412s Year: 2003 The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Thromboxane B2 (TXB2) urine levels during long term treatment with montelukast (M) in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 353s Year: 2001